Literature DB >> 7918590

Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord.

L Svennerholm1, K Boström, P Fredman, B Jungbjer, A Lekman, J E Månsson, B M Rynmark.   

Abstract

Glycosphingolipids were determined in human spinal cord, cauda equina and femoral nerve of 10 subjects aged 20-70 years and in dorsal and ventral roots of four subjects aged 17-60 years. Myelin was isolated from corresponding tissue. Axons were isolated from the four specimens of dorsal and ventral roots. The concentration (mean and standard error of mean) of gangliosides in spinal cord was 0.80 +/- 0.03 mumol sialic acid/g fresh tissue, in cauda equina 0.40 +/- 0.02 mumol/g and in femoral nerve 0.23 +/- 0.01 mumol/g. In spinal cord only trace amounts of glycosphingolipids of the lacto series were found, and the ganglioside pattern differed from that in cerebral white matter by a relatively high proportion of GD3 and a low proportion of GD1a. The ganglioside patterns were almost identical in cauda equina and femoral nerve--the major ganglioside being 3'-LM1, 0.07 and 0.04 mumol/g respectively. Another ganglioside of the lacto series, 3'-HexLM1, was 25% of 3'-LM1. Peripheral nerve also contained three acidic glycosphingolipids in addition to sulfatide--LK1 and HexLK1 belonging to the glycosphingolipid lacto series and containing glucuronyl-3-sulfate instead of sialic acid, and inositolphosphoryl galactosylceramide. The dorsal (sensory) and ventral (motor) roots had the same major membrane lipid composition but the ganglioside concentration was 30% higher in sensory than motor nerve and myelin. The patterns of gangliotetraose gangliosides were, however, the same in motor and sensory myelin and axons. The ceramide composition of the gangliosides is also reported.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7918590     DOI: 10.1016/0005-2760(94)90034-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  56 in total

1.  Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth.

Authors:  Kazim A Sheikh
Journal:  Small GTPases       Date:  2011-07-01

2.  Pathogenesis and treatment of immune-mediated neuropathies.

Authors:  Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

3.  Anti-GD2 Strategy in the Treatment of Neuroblastoma.

Authors:  Richard K Yang; Paul M Sondel
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

4.  Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.

Authors:  Alice L Yu; Andrew L Gilman; M Fevzi Ozkaynak; Wendy B London; Susan G Kreissman; Helen X Chen; Malcolm Smith; Barry Anderson; Judith G Villablanca; Katherine K Matthay; Hiro Shimada; Stephan A Grupp; Robert Seeger; C Patrick Reynolds; Allen Buxton; Ralph A Reisfeld; Steven D Gillies; Susan L Cohn; John M Maris; Paul M Sondel
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

5.  Molecular mimicry: sensitization of Lewis rats with Campylobacter jejuni lipopolysaccharides induces formation of antibody toward GD3 ganglioside.

Authors:  Seigo Usuki; Stuart A Thompson; Michael H Rivner; Kyoji Taguchi; Keiko Shibata; Toshio Ariga; Robert K Yu
Journal:  J Neurosci Res       Date:  2006-02-01       Impact factor: 4.164

Review 6.  Anti-GD2 antibody therapy for GD2-expressing tumors.

Authors:  Fariba Navid; Victor M Santana; Raymond C Barfield
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

Review 7.  Autoimmune responses in peripheral nerve.

Authors:  H P Hartung; H Willison; S Jung; M Pette; K V Toyka; G Giegerich
Journal:  Springer Semin Immunopathol       Date:  1996

8.  Ocular abnormalities in patients treated with a novel anti-GD2 monoclonal antibody, hu14.18K322A.

Authors:  Brian C Tse; Fariba Navid; Catherine A Billups; Thomas O'Donnell; Mary E Hoehn
Journal:  J AAPOS       Date:  2015-03-26       Impact factor: 1.220

9.  Combined sialic acid and histone deacetylase (HDAC) inhibitor treatment up-regulates the neuroblastoma antigen GD2.

Authors:  Renske J E van den Bijgaart; Michiel Kroesen; Melissa Wassink; Ingrid C Brok; Esther D Kers-Rebel; Louis Boon; Torben Heise; Monique van Scherpenzeel; Dirk J Lefeber; Thomas J Boltje; Martijn H den Brok; Peter M Hoogerbrugge; Christian Büll; Gosse J Adema
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

10.  Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.

Authors:  Andrew L Gilman; M Fevzi Ozkaynak; Katherine K Matthay; Mark Krailo; Alice L Yu; Jacek Gan; Adam Sternberg; Jacquelyn A Hank; Robert Seeger; Gregory H Reaman; Paul M Sondel
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.